Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.
Kim Nash is an editor who manages a team of reporters covering cybersecurity and data-privacy issues for The Wall Street Journal's Pro unit in New York. Her team’s stories explore how companies ...
Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive form ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback